Dexcom to Feature Health Innovations at CES 2027
Dexcom is confirmed as an exhibitor for the upcoming CES 2027, which will showcase an expanded health experience featuring over 115 exhibitors in the digital health sector.
Stocks · News reference
Dexcom has encountered public backlash and legal action following an in-app notification that required users to accept updated terms or lose access to their continuous glucose monitoring (CGM) application.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Dexcom is confirmed as an exhibitor for the upcoming CES 2027, which will showcase an expanded health experience featuring over 115 exhibitors in the digital health sector.
DexCom, Inc. announced that management will provide a company update at the Jefferies Global Healthcare Conference in London on November 17, 2026.
Health Canada has granted approval for the use of the Dexcom G7 Continuous Glucose Monitoring System with the myLoop automated insulin delivery system, powered by CamAPS FX.
Kevin Sayer, the Executive Chairman of the Dexcom board and former CEO, has been appointed to the board of directors of precision oncology company Guardant Health, Inc.
India's continuous glucose monitoring market is projected to grow at a CAGR of 11.90% from 2027-2032, reaching USD 452.9 million by 2032. The market expansion is driven by growing adoption of sensor-based monitoring, digital healthcare integration, and expanding diabetes management programs. However, high device costs and limited reimbursement coverage remain barriers to wider adoption.
Several financial institutions, including UBS, Barclays, Canaccord Genuity, StoneX, and JP Morgan, updated their price targets for DexCom, Inc. following the company's recent quarterly earnings report.